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ABSTRACT 
Centbutindole is a new antipsychotic agent related to butyrophenone group. The drug is dopamine 
antagonist but it also blocks 5HT2 receptors. Clinically the drug has passed through phase I, II & III 
clinical trials successfully and it has shown effective antipsychotic activity in schizophrenic patients. 
In the present study the drug was compared with risperidone in a double blind manner for a period of 
8 weeks to assess the efficacy in schizophrenic patients. Patients of schizophrenia evaluated on 
PANSS, CGI & UKU side effect rating scale weekly Out of 44 patients included in study, 38 completed 
the trial. The intergroup comparison of two drugs showed that centbudindole and risperidone have 
similar onset of antipsychotic action as both the drugs showed significant decrease in the total 
PANSS score as well as positive syndrome score, negative syndrome score and general 
psychopathology score from 2nd week onwards. The scores in both the groups showed a steady and 
significant decline from 2nd week to 8th week of study. The present study showed that centbutindole 
has similar improvement on clinical global impression with risperidone. The side effect profile was 
similar in the two drugs except dystonia (5 patients in centbutindole vs 1 patient in risperidone 
group). The findings of present study shows that Centbutindole could be used as a promising new 
drug for treatment of schizophrenia in place of a typical antipsychotics as it has shown improvement 
on negative symptoms similar to risperidone. 
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Centbutindole is a new antipsychotic 
(compound 70/343) 2-[Y-(P-fluorobenzoyl)Propyl]-
1,2,3,4,6,7,12,12a octahydropyrazino(2',1',:6,1) 
pyrido (3~4-(5) indole related to butyrophenone 
group (Saxena et al.,1973). It is a light yellow 
crystalline compound with molecular weight of 
391.49 which is soluble in dilute acids or organic 
compounds. 
Preclinical^ it has been found to block 
amphetamine induced hyper activity/stereotypy 
and secondary conditioned avoidance 
responses.These effects have been found in doses 
lower than those required for chlorpromazine and 
haloperidol. The drug is primarily a dopamine 
antagonist but it also blocks 5HT2 receptors 
(Gulati et al., 1988). The L-isomer of centbutindole 
is many times more active than the d-isomer 
(Singh et al., 1977). Clinically the drug has passed 
through phase I, II & III clinical trials successfully 
and it has shown effective antipsychotic activity 
in schizophrenic patients (Doonga ji et al, 1983) 
The peak serum levels were reached at 4 hours 
and the plasma half life was 12 hours(Paliwal et 
al.,1992) The present study has been conducted 
with aims to compare the antipsychotic efficacy 
with regards to positive and negative symptoms 
of schizophrenia as well as side effect profile of 
centbutindole and risperidone. 
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MATERIAL AND METHOD 
A comparative double blind trial was 
designed. Stringent selection criteria were applied 
in this study to obtain a homogenous sample. 
The subjects were schizophrenic patients 
diagnosed according to ICD-10 DCR criteria. 
Patients satisfying both the inclusion and 
exclusion criteria were admitted in the hospital 
and randomized according to a predetermined 
randomization schedule to receive either 
centbutindole or risperidone for a period of 8 
weeks. Patient were assessed weekly for clinical 
symptomatology and side effects. The patients 
of schizophrenia having no prior drug treatment 
between age of 18 to 50 years, willing to accept 
oral medication were included in the study. 
Patients with hyper sensitivity to study drug, 
pregnancy or lactation, coexisting severe organic 
disease, depression, drug abuse or mental 
subnormality and patients requiring parenteral 
medication or ECT were excluded from the study. 
Each patient/guardian gave informed written 
consent before inclusion in the study. The eligible 
patients were subjected to a detailed base line 
clinical , hematological and biochemical 
investigations. There patietns were randomly 
allocated to receive either 4.5mg of centbutindole 
or 6 mg of risperidone. The drug was formulated 
in capsules identical in colour, shape and size. 
Each capsule contained centbutidole (1.5 mg) or 
risperidone (2 mg). Initial dose was 1 Capsule 
twice a day for three days increasing to 1 capsule 
in the morning and 2 capsule at bed time through 
out the study period of 8 weeks.During this study 
period each patient was evaluated on positive and 
negative syndrome scale (PANSS), clinical global 
impression scale and UKU side effect rating scale. 
At the end of the study period i.e. 8th week 
patients were evaluated again by detailed history, 
physical examination and laboratory investigations 
to determine any changes in the physical or 
biochemical status of the patient. Trihexyphenidyl 
(6 mg per day) was used as adjuvant medication 
at the time of appearance of esctrapyramidal 
symptoms. 
RESULTS 
A homogenous sample of 80 schizophrenic 
patients were screened . Forty four subjects 
fulfilled the criteria and were included in the study. 
They were randomly assigned to the two treatment 
groups of centbutindole and risperidone 
respectively i.e. 22 patient in each group. Four 
out of 44 patients dropped out during the study 
and 2 out of 44 patients were withdrawn from the 
study. Amongst dropped out 2 patients belong to 
each group while amongst terminated both the 
terminated patients were of centbutindole group. 
Finally 38 patients completed the study i.e. 18 
patients in centbutindole group and 20 patients in 
risperidone group. 
The sociodemographic and clinical variables 
of the sample are given in (Table no.1). This shows 
that there was no significant difference between 
centbutindole and risperidone groups with respect 
to age, sex , marital status, onset, numbers of 
episodes, clinical diagnosis and duration of 
illness. 
The onset of effect was observed in both 
the study drugs from 2nd week onwards in relation 
to PANSS factors like total PANSS score, positive 
syndrome scale, negative syndrome scale, general 
psychopathology, activation, paranoid belligerence 
thought disturbance, depression and anergia 
(Table no.2). The steady decline in scores was 
observed from 3rd week to 8th week of study with 
both drugs. In relation to thought disturbance the 
significant improvement was observed from 3rd 
week onwards with centbutindole and 4th week 
onwards with risperidone. The depression (4th 
week) and anergia (2nd week) improved earlier to 
risperidone than with centbutindole. But these 
differences were no more perceptible at 6th week 
onwards. 
Overall improvement of individual patients 
was assessed on CGI scale (Table no.3) on 
comparing the severity of illness at beginning of 
study in centbutindole group 12 patients were 
severely ill, 5 markedly ill and one was moderately 
ill. While in risperidone group 8 patients were 
severely ill, 9 markedly ill and 3 were moderately COMPARATIVE EFFICACY OF CENTBUTINDOLE & RISPERIDONE IN SCHIZOPHRENIA 
TABLE 1 
SOCIO-DEMOGRAPHIC & CLINICAL VARIABLES OF THE STUDY 
Variables 
Age(Mean±SD) 
Sex(Male/Female) 
Marital Status 
Married/Unmarried/Single 
Onset (Insidious/Acute) 
Episode (lst/>1) 
Duration 
(<2yrs/>=2 yrs) 
Clinical Diagnosis 
(Paranoid/Non-paranoid) 
Family H/O Schizo. 
(Present/Absent) 
Centbutindole 
(n=22) 
27.22 yrs. 
±8.69 
15(68%):7(32%) 
9(41%):11(50%):2 
13(59%):9(41%) 
10(45%): 12(55%) 
9(41%): 13(59%) 
10(45%):12(55%) 
3(14%). 19(86%) 
Risperidone 
(n=22) 
30 68 yrs 
±8.78 
17(77%):5(23%) 
16(73%):6(27%):0 
16(73%):6(27%) 
11 (50%): 11 (50%) 
8(36%):14(64%) 
11 (50%). 11 (50%) 
4(18%): 18(82%) 
ill. At the end of study i.e. 8th week global 
improvement was assessed and it was observed 
that in centbutindole group 8 patients were very 
much improved, another 8 much improved, one 
minimally improved and another one had no 
improvement. While in risperidone group 12 
patients were very much improved, 5 much 
improved and 3 minimally improved. 
Side effect profile of the 2 drugs has been 
given in Table 4. Side effect analysis revealed that 
there was no significant difference in the side effect 
profile of the 2 drugs except on the neurologic 
sub scale of UKU. Five (28%) patients developed 
dystonia in centbutindole group while only one 
patient (5%) developed dystonia in risperidone 
group. 
DISCUSSION 
Out of 44 patients, 4 dropped out and 2 
patients were terminated from the study. There 
was no obvious reason for dropping out besides 
absconding from the wards in both groups. This 
may be attributed to nature of the illness and 
latency of antipsychotic activity of both the drugs 
because all the patients dropped out either in the 
1st week or at the beginning of 2nd week The 
reason for termination in 1 patent of centbutindole 
group was developement of tremor and salivation 
not controlled by 6mg of trihexyphenidyl and 
parents wish to opt out from the study Another 
patient of the same group required parenteral 
medication to control her agitation. The inter group 
comparison of two drugs showed that 
centbutindole and risperidone have similar onset 
of antipsychotic action as both the drugs showed 
significant decrease in the total PANSS score as 
well as positive syndrome, negative syndrome and 
general psychopathology scores from 2nd week 
onwards. The scores in both the groups showed 
a steady and significant decline from 2nd to 8th 
weeks of study. Although there are no treatments 
with proven efficacy for negative symptoms 
(Chouinard et al .1993 Marder,1996), 
centbutindole and risperidone in present study 
have been found equieffective for negative 
367 R.CHANDRA eta/. 
TABLE 2 
CHANGES FROM BASE LINE IN PANSS SCORES 
Item 
Total PANSS 
OS 
RS 
Positive Sym 
CB 
RS 
Negative Sym 
CB 
RS 
General Psycho 
C8 
RS 
Paranoid belli 
CB 
RS 
Thought Distur 
CB 
RS 
Activation 
CB 
RS 
Anergia 
CB 
RS 
Depression 
CB 
RS 
week 0 
MeamSD 
98.36±16.74 
87.81±16.92 
23.95l6.23 
20.9514.95 
28.01i10.36 
23.95i8.97 
46.59i9.35 
42.41i8.17 
11.41±2.97 
10.09i3.70 
12.59i3.92 
10.3613.75 
6.3U2.16 
5.6313.30 
13.45*3.53 
11.9014.85 
9.70i3.61 
8.4U4.02 
weekl 
94.57i20.94 
79.31±18.48 
21.90±6.95 
18.71i4.58 
25.71i11.03 
21.0218.80 
44.8019.91 
38.23i8.23 
10.7113.42 
8.7713.39 
12.1914.31 
9.45±3.97 
5.09i2.28 
3.9512.03 
13.2814.30 
11.3614.03 
9.2213.25 
8.2813.12 
week2 
76.33i18.27 
66.2121.69 
17.28l6.42 
16.1515.52 
22.57l9.80 
17.48±9.51 
36.80±9.23 
32.25i9.04 
7.67±3.31 
7.50*3.63 
9.71±4.24 
8.55±3.95 
4.23±2.49 
3.50±0.89 
11.7114.19 
9.8014.73 
8.8113.27 
7.1513.03 
week4 
61.10122.03 
51.60120.2 
14.0217.01 
10.9514.65 
17 5518.09 
14.0017.74 
31.95111.30 
26.4518.76 
6.9514.19 
5.0013.08 
6.7513.85 
5.9512.84 
3.7511.68 
3.5010.89 
9.2013.72 
8.6013.98 
7.0513.05 
6.6012.46 
week6 
50.89121.21 
44.80115.34 
10.6316.91 
10.2516.15 
14.26i6.41 
11.0514.43 
26.4719.96 
23.5017.19 
5.0013.57 
3.5511.50 
5.7814.25 
6.1014.12 
3.6511.75 
3.3010.73 
8.2113.92 
6.4512.68 
5.7212.16 
6.5012.35 
week8 
45.16118.23 
42.25114.88 
9.3316.87 
10.1016.08 
12.6616.69 
10.7514.56 
23.22110.77 
21.2016.24 
3.7212.61 
3.8012.11 
5.5014.37 
6.0013.95 
3.2110.91 
3.2010.61 
7.6113.69 
6.5513.52 
5.5611.80 
5.3912.35 
symptoms. However, in the literature the evidence 
for negative symptoms improvment with 
risperdone (Chouinard etal.,1993,Marder,1996) is 
based on limited evidence and leaves them open 
to question. Given the fact that risperdone has 
fewer EPS and potentially superior antipsychotic 
efficacy for positive symptoms (Jalenques, I., 1995, 
Mc Evoy,1994), any improvement in negative 
symptoms that occur risperidone may be due to 
reduction of secondary negative symptoms 
(Lieberman et al., 1994). The similar explanation 
is possible for improvement in negative symptoms 
with centbutindole in the present study. 
The analysis of individual factors of PANSS 
showed no significant difference in paranoid 
belligerence and activation. However, a significant 
difference was observed with thought disturbance, 
depression and anergia. The significant 
improvement in thought disturbance was observed 
from 3rf week onwards with centbutindole and 4th 
week onwards with risperidone. So, it appears that 
thought disturbance was quicker to respond with 
centbutindole than risperidone. The results of 
phase III clinical trial support the findings of present 
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study. On depression and anergia the onset of 
therapeutic effect was earlier with risperidone as 
compared to centbutindole. However, at the end 
of six week both the drugs had equivalent effect 
on all these factors. 
TABLE 3 
COMPARISON OF SEVERITY OF ILLNESS AND 
GLOBAL IMPROVEMENT ON CGI SCALE 
Weeks Centbutindole Risperidone 
(N=18) (N=20) 
No. % No. % 
Seventy of illness 
0 Severity ill 12 67 8 40 
Markedly ill 5 28 9 45 
Moderately ill 1 6 3 15 
Global Improvement 
8th Very much 8 44 12 60 
improved 
Much improved 8 44 5 25 
Minimally improved 1 6 3 15 
No change 16 0 0 
On intergroup comparison of severity of 
illness at beginning and global improvement at 
the end of study no significant difference was 
observed on CGI scale in two groups. Thus present 
study showed that centbutindole has similar 
global impression with risperidone on CGI scale. 
Phase III clinical trial also showed no significant 
difference between centbutindole and haloperidol 
on CGI scale. Results of present study are also 
in consonance with pervious study by Singh et 
al., (1997). On a closer look , the initial severity 
of the illness on CGI scale was more in 
centbutindole group than the risperidone group in 
present trial. However, final evaluation of CGI scale 
reveals a similar response in both drugs. This 
observation indicates that even severely ill patients 
can be treated with centbutindole. 
Side effects were assessed on UKU side 
effects rating scale at the end of each week. In 
both the groups most commonly observed side 
effects were concentration difficulties, lassitude, 
sedation, dystonia, tremors, rigidity, increased 
salivation, weight gain, orthostatic dizziness and 
accommodation disturbances. Some of these 
symptoms like concentration difficulties, reduced 
sleep, inner unrest .emotional indifference, 
headache present at the first evaluation (not due 
to drugs) were improved with centbutindole and 
risperidone therapy in number of patients. This 
could probably be explained by considering that 
these symptoms were present during the 
schizophrenic illness. This finding is supported 
by an Indian study(Agarwaletal,1998). The side 
effect profile was comparable in the two drugs 
except that 5 (28%) patients experienced dystonia 
in centbutindole group and on other hand only 
1(5%) patient in risperidone group. In our study 
the incidence of dystonia for risperidone and 
centbutindole was with the range of various 
studies. These studies (Stern 1979; Keeper 1983; 
Arana, 1987) have reported appearance of dystonia 
in 4-94% patients on neuroleptic treatment not 
treated with anticholinergic agents. Previous 
studies with centbutindole have reported dystonia 
in 20% (dose upto 4 mg/day) of patients (Doonga 
ji et al., 1983). However, one study recently 
published (Singh et al., 1999) have found no 
incidence of dystonia. This difference can be 
attributed to low dose administration of 
centbutindole (3 mg/day) in first 2 weeks of the 
study. 
The majority of side effects were mild to 
moderate in severity, manageable and could be 
controlled by a fixed dose of 6 mg of 
trihexyphenidyl except one patient in 
centbutindole group. When the patient developed 
severe neurologic side effects not responding to 
6 mg of trihexyphenidyl and resulted in premature 
termination of the patient from the study. Majority 
of side effects appeared in close proximity of their 
standard time of appearance in both the drugs. 
For instance asthenia, lassitude, akathisia, 
orthostatic dizziness appeared at the end of first 
week in both of the drugs except for asthenia in-
risperidone group where no consistent pattern of 
appearance was noted. Similarly rigidity, tremors 
and hypersalivation were observed dunng second 
week in most of the cases in both drugs 
The new drug centbutindole shows similar 
onset of antipsychotic efficacy as compared to 
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TABLE 4 
INDIVIDUAL SIDE EFFECT PROFILE OF BOTH DRUGS 
Side Effects 
Weight gain(1 -2kg/month) 
Increased salivation 
Tremors 
Lassitude 
Sedation 
Concentration difficulties 
Rigidity 
Increased duration of sleep 
Dystonia 
Hypokinesia 
Orthostatic dizziness 
Accomodation disturbance 
Constipation 
Increased sweating 
Inner unrest 
Amenorrhea 
Depression 
Akathisia 
Occulogyric spasms 
Decreased salivation 
Headache 
Decreased sexual desire 
Erectile dysfunction 
Rash/pruritus 
Centbutindole (N= 18) 
No. 
14(Mean 2.3kg ±3.48) 
12 
6 
6 
7 
7 
5 
8 
5 
5 
8 
2 
4 
3 
4 
2 
2 
2 
% 
78 
67 
33 
33 
39 
39 
28 
44 
28 
28 
44 
11 
22 
17 
22 
11 
11 
11 
6 
6 
6 
6 
6 
6 
Risperidone (N=20) 
No 
9(Mean2 3kg±2 81) 
11 
9 
9 
4 
6 
7 
6 
1 
4 
7 
5 
3 
1 
2 
1 
4 
2 
1 
2 
2 
1 
1 
0 
% 
45 
55 
45 
45 
20 
30 
35 
30 
5 
20 
35 
25 
15 
5 
10 
5 
20 
10 
5 
10 
10 
5 
5 
0 
risperidone which is also a new atypical 
antipsychotic. Therefore, centbutindole could be 
considered treatment of schizophrenia along with 
atypical antipsychotic. It has shown improvement 
in negative symptoms essentially similar to 
risperidone. 
Lastly , the present study has its own 
limitations for instance, smaller sample size and 
duration. More large, long term controlled studies 
are required to further evaluate the antipsychotic 
properties and long term side effects of 
centbutindole and also to compare with other 
atypical antipsychotics. 
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